Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment.
Saved in:
| Title: | Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment. |
|---|---|
| Authors: | Schieber T; The University of Kansas Cancer Center, Westwood, KS., Hobbs J; Avera McKennan Hospital and University Health Center /Avera Cancer Institute, Sioux Falls, SD., Campaign-Mauser J; Huntsman Cancer Institute, Salt Lake City, UT., Jones EJ; Huntsman Cancer Institute, Salt Lake City, UT., Olinger A; Nebraska Medical Center, Omaha, NE., Bortka B; Saint Luke's Hospital of Kansas City, Kansas City, MO., Gustafson B; Saint Luke's Hospital of Kansas City, Kansas City, MO., Blocker S; The University of Kansas Cancer Center, Westwood, KS., Kim D; The University of Kansas Cancer Center, Westwood, KS., Mullangi S; The University of Kansas Cancer Center, Westwood, KS., Lekkala MR; The University of Kansas Cancer Center, Westwood, KS., Parikh R; The University of Kansas Cancer Center, Westwood, KS., Huang C; The University of Kansas Cancer Center, Westwood, KS., Neupane P; The University of Kansas Cancer Center, Westwood, KS., Li H; The University of Kansas Cancer Center, Westwood, KS. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2026 Jan; Vol. 10, pp. e2500849. Date of Electronic Publication: 2026 Jan 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
